Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCRinhibitor setting: aUKwide analysis
- 15 February 2019
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 185 (4) , 656-669
Abstract
Summary: Venetoclax is aBCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi‐centre retrospective analysis of 105 R/RCLLpatients who received venetoclax pre‐National Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1–15). 48% hadTP53disruption. At ≥2 lines, 60% received a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3‐kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no priorBTKi, and 10% received both. Patients discontinued B cell receptor inhibitor (BCRi) because of toxicity in 44% and progression in 54%. Tumour lysis syndrome risk was low, intermediate or high in 27%, 25%, and 48% respectively. Overall response was 88% (30% complete response [CR]). The overall response rate was 85% (CR23%) inBTKi‐exposed patients, 92% (CR38%) in Pi3Ki‐exposed patients and 80% (CR20%) in both (P = 0·59). With a median follow‐up of 15·6 months, 1‐year progression‐free survival was 65·0% and 1‐year overall survival was 75·1%. Dose reduction or temporary interruption did not result in an inferior progression‐free or discontinuation‐free survival. Risk of progression or death after stopping a priorBCRi for progression was double compared to those stopping for other reasons (predominantly toxicity) (Hazard Ratio 2·01P = 0·05). Venetoclax is active and well tolerated in R/RCLLpost ≥1BCRi. Reason(s) for stoppingBCRi influences venetoclax outcomes.Keywords
Funding Information
- Oxford NIHR Biomedical Research Centre
This publication has 15 references indexed in Scilit:
- Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapyBlood, 2018
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisHaematologica, 2018
- Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation projectCytometry Part B: Clinical Cytometry, 2018
- Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patientsAnnals of Oncology, 2017
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2016
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibBlood, 2015
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2014
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- The Tumor Lysis SyndromeNew England Journal of Medicine, 2011
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958